Gene-Edited T Cell Therapy Players Battle Safety Doubts
Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused…
Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused…
CAR-T therapy has been hailed as a cure for cancer, but what really is this…
Natural killer cells are becoming a hot topic in the booming cancer cell therapy scene,…
Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American…
Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In…
An off-the-shelf, gene edited CAR T-cell therapy, developed by the French biotech Cellectis, could be…
Cellectis is developing a new type of chimeric antigen receptor that could improve the production…
Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in…
Despite all the hype, CRISPR is still not in the clinic as a standalone therapy…
Update (16/02/2018): On top of the European patent it got last July, Cellectis now also…
Most CAR-T stocks rose on the news that Big Biotech Celgene has plans to acquire…
Here's a closer look at the French biotech ecosystem in 2017, which remains one the…